MAP2K7 and fibrosarcoma: The introduction of targeted therapies against rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors has revolutionized treatment for patients whose melanoma harbors a BRAF V600 gene mutation, especially when these drugs are used in combination.1